Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05967052
Other study ID # NIGRIR_001POSTCOVID
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date October 24, 2023
Est. completion date March 1, 2028

Study information

Verified date November 2023
Source National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
Contact Beata Tarnacka, Prof, Md, PhD
Phone 22 6709176
Email klinika.rehabilitacji@spartanska.pl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-center, prospective, randomized, double-blind (pharmacotherapy), placebo-controlled, and comprehensive rehabilitation phase II clinical trial to determine the usefulness of pregabalin in a new indication (post-COVID chronic fatigue syndrome). Patients will be randomized in a 1:1:1:1 ratio to pregabalin (75-300 mg daily in two divided doses), comprehensive rehabilitation with a placebo drug, comprehensive rehabilitation with pregabalin (75-300 mg in two divided doses), or placebo (two divided doses) for 6 months (177-187 days). There will be 4 outpatient visits to the research center and 12 telephone consultations. The procedures and assessments performed as part of the study are listed in the study schedule. It is planned to include 132 patients in the study, which, assuming a 10% level of non-completion of the program, will result in the examination of 120 patients (30 in each arm). Patients will be recruited during an outpatient medical consultation with a general practitioner or neurologist, psychiatrist, psychologist or other specialists, as well as with the use of information materials in the form of leaflets and advertisements on the Internet.


Recruitment information / eligibility

Status Recruiting
Enrollment 132
Est. completion date March 1, 2028
Est. primary completion date March 1, 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. The patient correctly gave written informed consent to participate in the study; 2. Men or women between the ages of 18 and 65 inclusive at the time of signing the informed consent; 3. Patient after a minimum of 6 months from the documented detection of SARS-CoV-2 infection (document confirming the history of the disease, including a positive result of the PCR or antigen test, certificate of convalescence; medical documentation confirming the infection; the condition is also considered fulfilled in the case of documented infection asymptomatic); 4. During the screening, the patient meets the criteria for the diagnosis of chronic fatigue syndrome (CFS) according to the National Academy of Medicine (2015); 5. Women: a) incapable of having children (post-menopausal or child-bearing, subjected to permanent sterilization); (b) of childbearing potential with a negative pregnancy test result at screening and using a highly effective method of contraception throughout the IMP use and for 7 days after the last IMP use. 6. The patient agrees to participate in all activities provided for in the study. 7. The patient is able to understand the information presented and give informed consent to participate in the study prior to screening. Exclusion Criteria: 1. Vital functions disorders; 2. Documented hypersensitivity to pregabalin or any of the excipients of the formulation (i.e., lactose); 3. Moderate or severe depression during treatment or present during psychiatric evaluation at baseline; 4. Concurrent treatment with opioids or other antiepileptic drugs (including tramadol, buprenorphine, morphine, oxycodone, gabapentin, duloxetine); 5. Pregnant or breastfeeding women.

Study Design


Intervention

Drug:
Pregabalin
Pregabalin pharmacotherapy
Behavioral:
Independent walking training
Independent walking training
Drug:
Placebo
Placebo
Behavioral:
Gradual movement therapy in the ward
Gradual movement therapy in the ward
Telerehabilitation
Telerehabilitation
Psychotherapy
Psychotherapy

Locations

Country Name City State
Poland Centrum Wsparcia Badan Klinicznych Warsaw Mazowieckie

Sponsors (2)

Lead Sponsor Collaborator
National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland Medical Research Agency, Poland

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Other The change in the profile of the examined inflammatory cytokines The exploratory endpoint is the change in the profile of the examined inflammatory cytokines in the 3rd and 6th month of the study in relation to the result before the start of the study. 3 months and 6 months
Other Number of adverse events and the number and percentage of patients who experienced adverse events Number of adverse events and the number and percentage of patient who experienced adverse events 3 months and 6 months
Other Number of adverse events and the number and proportion of patients who experienced treatment-related adverse events Number of adverse events and the number and proportion of patients who experienced treatment-related adverse events 3 months and 6 months
Other Number of serious adverse events and number and proportion of patients with serious adverse events. Number of serious adverse events and number and proportion of patients with serious adverse events. 3 months and 6 months
Other Number of serious adverse events and the number and proportion of patients who experienced treatment-related serious adverse events. Number of serious adverse events and the number and proportion of patients who experienced treatment-related serious adverse events. 3 months and 6 months
Other Number and percentage of patients who discontinued participation in the study due to an adverse event - changes in laboratory parameters and basic vital signs. Number and percentage of patients who discontinued participation in the study due to an adverse event - changes in laboratory parameters and basic vital signs. 3 months and 6 months
Primary Change in fatigue intensity expressed as a difference in Multidimensional Fatigue Inventory-20 (MFI-20) score Change in fatigue intensity expressed as a difference in Multidimensional Fatigue Inventory-20 (MFI-20) score at 3 and 6 months of the study relative to the baseline score 3 months and 6 months
Primary Walking distance as a difference in score from the 6 Minute Walking Test Walking distance as a difference in score from the 6 Minute Walking Test at 3 and 6 months compared to baseline 3 months and 6 months
Secondary Change in the level of satisfaction with life expressed in the form of the result of the Satisfaction with Life Scale (Juczynski) Change in the level of satisfaction with life expressed in the form of the result of the Satisfaction with Life Scale (Juczynski) in the 3rd and 6th month of the study in relation to the result on the day of the study 3 months and 6 months
Secondary Change in the result obtained in the "Beck Depression Inventory (BDIII)" study Change in the result obtained in the "Beck Depression Inventory (BDIII)" study in the 3rd and 6th month of the study in relation to the result on the day of the study commencement. 3 months and 6 months
Secondary Change in the result obtained in the anxiety test - State and Trait Anxiety Inventory (STAI) Change in the result obtained in the anxiety test - State and Trait Anxiety Inventory (STAI) in the 3rd and 6th month of the study in relation to the result on the day of the study commencement. 3 months and 6 months
Secondary Change in the degree of acceptance of the disease assessed by the Acceptance of Illness Scale (Juczynski) i Change in the degree of acceptance of the disease assessed by the Acceptance of Illness Scale (Juczynski) in the 3rd and 6th month of the study in relation to the result on the day of starting the study 3 months and 6 months
Secondary Change in the result of the CCT test Change in the result of the CCT test in the 3rd and 6th month of the study compared to the result on the day of starting the study. 3 months and 6 months
Secondary Change in neuropsychological assessment expressed by the change in the result of the Wisconsin Card Sorting Test (WCST) Change in neuropsychological assessment expressed by the change in the result of the Wisconsin Card Sorting Test (WCST) in the 3rd and 6th month of the study compared to the result on the day of the study commencement. 3 months and 6 months
Secondary Change in the result of the RFFT test Change in the result of the RFFT test in the 3rd and 6th month of the study compared to the result on the day of starting the study. 3 months and 6 months
Secondary Change in the WAIS-R intelligence test result Change in the WAIS-R intelligence test result in the 3rd and 6th month of the study in relation to the result on the day of the study commencement 3 months and 6 months
Secondary Change in reaction time expressed by the Stroop interference test Change in reaction time expressed by the Stroop interference test in the 3rd and 6th month of the study compared to the result on the day of the study start. 3 months and 6 months
Secondary Change in the assessment of the quality of gait Change in the assessment of the quality of gait in the 3rd and 6th month of the study in relation to the result on the day of the beginning of the study 3 months and 6 months
Secondary Change in walking speed Change in walking speed in the 3rd and 6th month of the study in relation to the result on the day of the study. 3 months and 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05454683 - Melatonin and Zinc Administration on Cardinal Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome N/A
Completed NCT01686074 - Motor Control in Chronic Fatigue Syndrome and Fibromyalgia N/A
Completed NCT02075489 - Acupressure for Pain Management and Fatigue Relief in Gulf War Veterans N/A
Completed NCT01651754 - Humoral and Cellular Immune Responses After Influenza Vaccination in Patients With Postcancer Fatigue and in Patients With Chronic Fatigue Syndrome N/A
Completed NCT00540254 - Behavioral Insomnia Therapy With Chronic Fatigue Syndrome Phase 1/Phase 2
Active, not recruiting NCT00071162 - Genetics of Fibromyalgia N/A
Withdrawn NCT04870476 - Feasibility and Acceptability of the Internet-delivered Treatment "One Step at the Time" for Bodily Distress Syndrome N/A
Completed NCT05730660 - Quercetin Phytosome® Chronic Fatigue Syndrome N/A
Recruiting NCT04542161 - Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Phase 2
Recruiting NCT03807973 - Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes. Phase 1
Recruiting NCT05719493 - Effectiveness and Health Benefits of a Nutritional, Chronobiological and Physical Exercise Intervention in Fibromyalgia and Chronic Fatigue Syndrome (SYNCHRONIZE +) N/A
Terminated NCT01730495 - Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome Phase 2
Completed NCT01156909 - B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome Phase 2
Completed NCT01650636 - Patient-Partner Stress Management Effects on Chronic Fatigue Syndrome Symptoms and Neuroimmune Process N/A
Completed NCT01046370 - A Pilot Study of Amygdala Retraining Program in Patients With Chronic Fatigue Syndrome, Chronic Fatigue and Fibromyalgia N/A
Completed NCT00100412 - Hyporeactivity and Gulf War Illness N/A
Recruiting NCT06128967 - A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial Phase 3
Completed NCT02669212 - Myalgic Encephalomyelitis Chronic Fatigue at the National Institutes of Health N/A
Not yet recruiting NCT06011135 - Exploring Worry in CFS/ME
Completed NCT03844412 - Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments Phase 2